SYMATESE in the news
Advanced medical technology solutions
Tamtam found 10 recent articles about SYMATESE.
- Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets
Evolus expands its partnership with Symatese Aesthetics to distribute Estyme hyaluronic acid gel in Canada, Australia, and New Zealand, targeting a $500 million market.
- Evolus Expands into French Market
Evolus Inc. commercially launched Nuceiva, a product for deep frown lines, in France through a partnership with Symatese.
- Patrick Lichtlé (Sebbin, fabricant d'implants) : « Je suis désolé de placer les chirurgiens dans une situation inconfortable »
Sebbin, a silicone implant manufacturer owned by Symatese, is being liquidated, resulting in 125 job losses and supply concerns for surgeons.
- Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
Evolus has expanded its partnership with Symatese to exclusively distribute its Estyme dermal filler line across Europe and the UK starting in 2025.
- Appel à projets grandes causes - SYMATESE FOUNDATION - « la Santé et la Pédiatrie » |
Symatese Foundation launches a pediatric healthcare grant program offering financial support and employee expertise to French non-profits.
- L’Oréal et Symatese renforcent leur partenariat
L'Oréal and Symatese expanded their long-term R&D partnership to innovate in biomaterials and human tissue engineering.
- L’Oréal and Symatese strengthen their strategic research partnership on biomaterials
L’Oréal and Symatese have signed a long-term research agreement to co-develop advanced biomaterials for skin regeneration and non-animal product testing.
- L’Oréal et Symatese renforcent leur partenariat stratégique de recherche sur les biomatériaux
L'Oréal and Symatese are expanding their long-term R&D partnership to develop advanced biomaterials and reconstructed human tissue for medical and cosmetic research.
- Huit ans après le scandale PIP, la quête de la prothèse mammaire "la plus sûre du monde"
Symatese is leveraging computer simulation and automated production to launch a new generation of highly regulated, durable breast implants.
- Bornel : Symatese s’attaque au marché des implants mammaires
Symatese is returning to its roots in Bornel by launching a new line of breast implants after receiving clinical trial approval from health authorities.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like SYMATESE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies